Background:
Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease,
affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing
countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid
factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic
inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are
available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery
systems.
:
The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional
treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal
drugs in passive and receptor mediated active targeting against RA.
On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the
treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective
and appropriate treatment of this autoimmune disease.
Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview
